Euroapi SAS (EAPI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Euroapi SAS (EAPI) has a cash flow conversion efficiency ratio of 0.018x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€17.10 Million ≈ $19.99 Million USD) by net assets (€953.40 Million ≈ $1.11 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Euroapi SAS - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Euroapi SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read EAPI total debt and obligations for a breakdown of total debt and financial obligations.
Euroapi SAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Euroapi SAS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Laramide Resources Ltd
AU:LAM
|
-0.017x |
|
Hyundai Pharm
KO:004310
|
-0.038x |
|
Modiv Inc
NYSE:MDV
|
0.020x |
|
Ryvu Therapeutics SA
WAR:RVU
|
-0.522x |
|
Duta Intidaya Tbk PT
JK:DAYA
|
-0.595x |
|
msg life ag
HM:MSGL
|
-0.019x |
|
Condor Energies Inc.
TO:CDR
|
0.162x |
|
Huangshan Tourism Development Co Ltd B
SHG:900942
|
0.044x |
Annual Cash Flow Conversion Efficiency for Euroapi SAS (2019–2024)
The table below shows the annual cash flow conversion efficiency of Euroapi SAS from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Euroapi SAS (EAPI) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €983.50 Million ≈ $1.15 Billion |
€122.90 Million ≈ $143.68 Million |
0.125x | +2173.08% |
| 2023-12-31 | €927.70 Million ≈ $1.08 Billion |
€5.10 Million ≈ $5.96 Million |
0.005x | -86.38% |
| 2022-12-31 | €1.11 Billion ≈ $1.30 Billion |
€44.80 Million ≈ $52.38 Million |
0.040x | -42.91% |
| 2021-12-31 | €1.01 Billion ≈ $1.18 Billion |
€71.50 Million ≈ $83.59 Million |
0.071x | -27.75% |
| 2020-12-31 | €989.40 Million ≈ $1.16 Billion |
€96.80 Million ≈ $113.17 Million |
0.098x | +185.41% |
| 2019-12-31 | €1.02 Billion ≈ $1.19 Billion |
€34.90 Million ≈ $40.80 Million |
0.034x | -- |
About Euroapi SAS
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry;… Read more